ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Up 163.6% in February

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 154,773 shares, an increase of 163.6% from the February 12th total of 58,719 shares. Approximately 22.8% of the company’s shares are sold short. Based on an average daily trading volume, of 511,270 shares, the short-interest ratio is presently 0.3 days. Based on an average daily trading volume, of 511,270 shares, the short-interest ratio is presently 0.3 days. Approximately 22.8% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC acquired a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up approximately 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. Institutional investors own 1.19% of the company’s stock.

Analyst Ratings Changes

NDRA has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, January 21st. Ascendiant Capital Markets decreased their price objective on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, December 8th. Finally, Wall Street Zen raised shares of ENDRA Life Sciences to a “sell” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Trading Down 0.6%

NASDAQ NDRA traded down $0.02 on Thursday, reaching $3.36. The stock had a trading volume of 10,299 shares, compared to its average volume of 131,487. ENDRA Life Sciences has a 1 year low of $2.90 and a 1 year high of $11.96. The business has a 50 day moving average price of $4.04 and a 200 day moving average price of $4.91. The company has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.13 and a beta of -0.08.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.